Not yet recruitingPhase 3NCT05914194
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
Studying Narcolepsy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NLS Pharmaceutics
- Principal Investigator
- George Apostol, MD, MSNLS Pharmaceutics
- Intervention
- NLS-2(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05914194 on ClinicalTrials.govOther trials for Narcolepsy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07365566Pain Assessment in Patients With Idiopathic REM Sleep Behaviour DisorderUniversity Hospital, Toulouse
- RECRUITINGPHASE3NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda
- RECRUITINGNCT07299097Epidemiology of Narcolepsy Type 1 and Type 2 in SpainTakeda
- RECRUITINGPHASE2NCT06809803Extended-release Sodium Oxybate in ChildrenStanford University
- RECRUITINGPHASE1NCT06961266A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1Jazz Pharmaceuticals
- RECRUITINGPHASE2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda
- RECRUITINGNCT06292598Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control PopulationCentre Hospitalier Universitaire de Nīmes
- RECRUITINGNANCT06797284The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake DisordersSecond Affiliated Hospital of Soochow University